1. OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn's disease patients from the open-label extension study. Issue 2 (June 2019) Authors: Ferrante, M; Panes, J; Baert, F; Louis, E; Kaser, A; Gustafson, D; Hall, D; Böcher, WO; Herichova, I; Liao, X; Wallace, K; Kalabic, J; D'Haens, G Journal: Gut Issue: Volume 68:Issue 2(2019) Page Start: A64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP85 Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy. (21st January 2022) Authors: Baert, F J; Atreya, R; Kakuta, Y; Long, M; Roblin, X; Neimark, E; Song, A; Wallace, K; Kingys, K; Mallick, M; Liao, X; Lim, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn's Disease: Post-hoc analysis from the phase 3 study FORTIFY. (21st January 2022) Authors: Irving, P M; Abreu, M; Axler, J; Gao, X; Torres, J; Neimark, E; Song, A; Wallace, K; Kligys, K; Berg, S; Liao, X; Panaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY. (21st February 2022) Authors: Panaccione, R; Ferrante, M; Feagan, B G; Sandborn, W; Panes, J; Peyrin-Biroulet, L; Colombel, J; Schreiber, S; Dubinsky, M; Baert, F; Hisamatsu, T; Neimark, E; Huang, B; Liao, X; Song, A; Berg, S; Duan, W; Pang, Y; Pivorunas, V; Kligys, K Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Experimental research on influence of interstage oil injection in a dual-motor-driven two-stage screw air compressor. Issue 1 (1st November 2022) Authors: Liao, X; Wang, C; Yuan, H; Xing, Z Journal: IOP conference series Issue: Volume 1267:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Renal-infiltrating CD11c+ cells are pathogenic in murine lupus nephritis through promoting CD4+ T cell responses. (18th August 2017) Authors: Liao, X; Ren, J; Reihl, A; Pirapakaran, T; Sreekumar, B; Cecere, T E; Reilly, C M; Luo, X M Journal: Clinical and experimental immunology Issue: Volume 190:Number 2(2017:Nov.) Page Start: 187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses. (16th October 2017) Authors: Ren, J; Liao, X; Vieson, M D; Chen, M; Scott, R; Kazmierczak, J; Luo, X M; Reilly, C M Journal: Clinical and experimental immunology Issue: Volume 191:Number 1(2018:Jan.) Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. (27th May 2021) Authors: Bossuyt, P; Ferrante, M; Baert, F; Danese, S; Feagan, B G; Loftus Jr, E V; Panés, J; Peyrin-Biroulet, L; Ran, Z; Armuzzi, A; D'Haens, G R; Song, A; Neimark, E; Liao, X; Zhou, Q; Berg, S; Wallace, K; Panaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S033 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. (27th May 2021) Authors: Schreiber, S W; Ferrante, M; Panaccione, R; Colombel, J F; Hisamatsu, T; Lim, A; Lindsay, J O; Rubin, D T; Sandborn, W J; Neimark, E; Song, A P; Liao, X; Feng, T; Berg, S; Wallace, K; D'Haens, G R Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S026 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Electrical contacting of High-Velocity-Air-Fuel sprayed NiCr20 coatings by brazing. Issue 1 (May 2021) Authors: Bobzin, K; Wietheger, W; Heinemann, H; Liao, X; Vogels, C Journal: IOP conference series Issue: Volume 1147:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗